SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro Diagnostics

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2149758

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2149758

PCR Technologies Market by Technology, Product, Application, End User and Region - Global forecast to 2031

PUBLISHED:
PAGES: 293 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The PCR technologies market is projected to reach USD 21,430 million by 2031, up from USD 15,550 million in 2026, at a CAGR of 6.6% during 2026-2031.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsProduct, Technique, Application, End User, and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East & Africa

The PCR technologies market is evolving toward higher efficiency, accuracy, sensitivity, and versatility, driven by advances in sophisticated instrumentation and high-fidelity enzymes. Real-time PCR (qPCR) enables real-time monitoring and quantitative analysis, while RT-PCR supports RNA analysis, gene expression studies, and viral detection. Digital PCR (dPCR) is gaining importance for applications requiring highly precise and sensitive absolute quantification, further broadening PCR's applications across research and diagnostics.

PCR Technologies Market - IMG1

"qPCR to account for largest market share in 2025."

qPCR is expected to hold the largest share of the PCR technologies market due to its established use in diagnostics and research, where precise quantification is required. By combining PCR amplification with real-time monitoring using fluorescent dyes or probes, qPCR enables quantitative analysis of target DNA at each cycle. Its broad utility and established role in molecular diagnostics and research support its widespread adoption.

"Diagnostic laboratories to hold largest share in the market."

Diagnostic laboratories are expected to remain the largest end users of PCR technologies, driven by the growing need for rapid, sensitive, and accurate molecular testing. PCR is widely used for infectious disease detection, genetic testing, oncology, and disease monitoring. Rising testing volumes and demand for high-throughput workflows further support adoption. The shift toward automated, standardized, and integrated molecular testing systems is also strengthening PCR utilization in diagnostic laboratories.

North America is expected to retain the largest share of the PCR technologies market in 2026, supported by advanced healthcare infrastructure, strong adoption of molecular diagnostics, and substantial investments in genomics, precision medicine, and life-science research. The region also benefits from major PCR technology providers and the widespread use of PCR in clinical diagnostics, infectious disease testing, oncology, and genetic testing. Strong research capabilities and ongoing development of advanced PCR platforms further reinforce North America's market leadership.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-30%, Tier 2-42%, and Tier 3- 28%
  • By Designation: C-level-- 10%, Director-level-14%, and Others-76%
  • By Region: North America-40%, Europe-30%, Asia Pacific-22%, Rest of the World - 8%.

Prominent players in the PCR technologies market include F. Hoffman-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Germany), Sansure Biotech Inc. (China), Becton, Dickinson and Company (US), Analytik Jena AG (Germany), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), Standard Biotools (US), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Illumina, Inc. (US), Bioneer Corporation (South Korea), PerkinElmer Inc. (US), and Hologic Inc. (US).

Research Coverage

The research report examines the market by product, material end-users, and geography. This research covers factors that are driving market expansion, analyzes current industry prospects and challenges, and provides specifics on the competitive landscape, including market leaders and small and medium enterprises. This research also estimates the revenue of different market segments by considering five regions and micro-market analysis.

Reasons to Buy the Report

The report will provide market leaders and new entrants with valuable information on revenue estimates for the overall market and its subsegments. It will help stakeholders understand the competitive landscape, enabling them to position their businesses more effectively and develop appropriate go-to-market strategies. Additionally, the report offers insights into market dynamics, including key drivers, restraints, challenges, and opportunities.

This report provides insightful data on the following pointers:

  • Market Penetration: In-depth coverage of product portfolios offered by the top players in the PCR technologies market
  • Product Development/Innovation: In-depth coverage of product portfolios offered by the top players in the PCR technologies market
  • Market Development: Insightful data on profitable developing areas
  • Market Diversification: Details about recent developments and advancements in the PCR technologies market
  • Competitive Assessment: Extensive assessment of the products, growth tactics, revenue projections, and market categories of the top competitors
Show more
Product Code: AST 7880

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 SEGMENTS CONSIDERED
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS IN PCR TECHNOLOGIES MARKET
  • 2.4 HIGH-GROWTH SEGMENTS

3 PREMIUM INSIGHTS

  • 3.1 PCR TECHNOLOGIES MARKET OVERVIEW
  • 3.2 PCR TECHNOLOGIES MARKET, BY REGION
  • 3.3 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY COUNTRY AND PRODUCT
  • 3.4 GEOGRAPHIC SNAPSHOT OF PCR TECHNOLOGIES MARKET

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Laboratories Increasing outbreaks of infectious diseases/viral persistence
      • 4.2.1.2 Development of miniaturized and portable point-of-care testing devices
      • 4.2.1.3 High demand for technologically advanced molecular diagnostics
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 Premium product pricing
      • 4.2.2.2 Dearth of skilled healthcare professionals
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Increased investments in laboratory infrastructure
      • 4.2.3.2 Rising number of applications in rare sequence detection
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Technical limitations
      • 4.2.4.2 Increased pricing pressure on market players
  • 4.3 UNMET NEEDS AND WHITE SPACES
  • 4.4 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 THREAT OF NEW ENTRANTS
    • 5.1.2 THREAT OF SUBSTITUTES
    • 5.1.3 BARGAINING POWER OF SUPPLIERS
    • 5.1.4 BARGAINING POWER OF BUYERS
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC OUTLOOK
    • 5.2.1 INTRODUCTION
    • 5.2.2 MACROECONOMIC INDICATORS
    • 5.2.3 GDP TRENDS AND FORECAST
    • 5.2.4 TRENDS IN GLOBAL PCR TECHNOLOGIES MARKET
  • 5.3 VALUE CHAIN ANALYSIS
    • 5.3.1 RESEARCH & DEVELOPMENT
    • 5.3.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING
    • 5.3.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
  • 5.4 ECOSYSTEM ANALYSIS
  • 5.5 PRICING ANALYSIS
    • 5.5.1 INDICATIVE PRICING REAL-TIME PCR INSTRUMENTS, BY KEY PLAYER, 2025
    • 5.5.2 INDICATIVE PRICING OF PCR TECHNOLOGY-BASED PRODUCTS, BY REGION, 2023-2025
      • 5.5.2.1 North America
      • 5.5.2.2 Europe
      • 5.5.2.3 Asia Pacific
      • 5.5.2.4 Rest of the World
  • 5.6 TRADE DATA ANALYSIS
    • 5.6.1 IMPORT DATA FOR HS CODE 3822
    • 5.6.2 EXPORT DATA (HS CODE 3822)
  • 5.7 KEY CONFERENCES & EVENTS, 2026-2027
  • 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.9 INVESTMENT AND FUNDING SCENARIO
  • 5.10 CASE STUDY ANALYSIS
    • 5.10.1 MULTIPLEX DETECTION OF KRAS MUTATIONS IN CELL-FREE DNA USING DIGITAL PCR
    • 5.10.2 PCR-BASED IDENTIFICATION OF ACINETOBACTER BAUMANNII SUPPORTS TARGETED INFECTION MANAGEMENT
  • 5.11 IMPACT OF US TARIFFS - PCR TECHNOLOGIES MARKET
    • 5.11.1 INTRODUCTION
    • 5.11.2 KEY TARIFF RATES
    • 5.11.3 PRICE IMPACT ANALYSIS
      • 5.11.3.1 Impact on countries/regions
      • 5.11.3.2 Impact on end-users

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACTS, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 KEY TECHNOLOGIES
    • 6.1.1 THERMAL CYCLERS
    • 6.1.2 REAL-TIME QUANTITATIVE PCR
    • 6.1.3 PORTABLE AND POINT-OF-CARE PCR
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 NEXT-GENERATION SEQUENCING
    • 6.2.2 MICROARRAYS
    • 6.2.3 LAB-ON-A-CHIP DEVICES
    • 6.2.4 ROBOTICS AND AUTOMATION
  • 6.3 PATENT ANALYSIS
  • 6.4 IMPACT OF AI/GEN AI ON PCR TECHNOLOGIES MARKET
    • 6.4.1 TOP USE CASES AND MARKET POTENTIAL
    • 6.4.2 BEST PRACTICES FOLLOWED BY COMPANIES IN PCR TECHNOLOGIES MARKET
    • 6.4.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION IN PCR TECHNOLOGIES MARKET
    • 6.4.4 INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS
    • 6.4.5 CLIENT'S READINESS TO ADOPT AI/GEN AI IN PCR TECHNOLOGIES MARKET
  • 6.5 SUCCESS STORIES AND REAL-WORLD APPLICATIONS

7 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR

  • 7.1 DECISION-MAKING PROCESS
  • 7.2 KEY STAKEHOLDERS IN BUYING PROCESS AND EVALUATION CRITERIA
    • 7.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 7.2.2 KEY BUYING CRITERIA
  • 7.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
  • 7.4 UNMET NEEDS OF VARIOUS APPLICATIONS
  • 7.5 REGULATORY LANDSCAPE
    • 7.5.1 REGULATORY ANALYSIS
      • 7.5.1.1 North America
        • 7.5.1.1.1 US
        • 7.5.1.1.2 Canada
      • 7.5.1.2 Europe
      • 7.5.1.3 Asia Pacific
        • 7.5.1.3.1 Japan
        • 7.5.1.3.2 China
        • 7.5.1.3.3 India

8 PCR TECHNOLOGIES MARKET, BY PRODUCT

  • 8.1 INTRODUCTION
  • 8.2 REAGENTS AND CONSUMABLES
    • 8.2.1 INCREASING USE OF DPCR-BASED ANALYTICAL PROCEDURES IN GENETIC RESEARCH AND FORENSICS TO DRIVE MARKET
  • 8.3 INSTRUMENTS
    • 8.3.1 RISING AVAILABILITY OF TECHNOLOGICALLY ADVANCED AND INNOVATIVE PCR INSTRUMENTS TO FUEL MARKET GROWTH
  • 8.4 SOFTWARE AND SERVICES
    • 8.4.1 GROWING DEMAND FOR SPECIALIZED PCR ANALYSIS SOFTWARE IN ONCOLOGY STUDIES AND FORENSICS TO SPUR MARKET GROWTH

9 PCR TECHNOLOGIES MARKET, BY TECHNIQUE

  • 9.1 INTRODUCTION
  • 9.2 REAL-TIME PCR
    • 9.2.1 RISING ADOPTION OF REAL-TIME PCR AMONG RESEARCHERS AND HEALTHCARE PROFESSIONALS TO PROPEL MARKET GROWTH
  • 9.3 CONVENTIONAL PCR
    • 9.3.1 COST-EFFECTIVENESS AND EASE OF USAGE IN ROUTINE CLONING, GENOTYPING, AND MUTATION ANALYSIS TO FUEL MARKET GROWTH
  • 9.4 DIGITAL PCR
    • 9.4.1 FASTER RESULTS WITH LOWER MARGIN ERRORS TO DRIVE ADOPTION
  • 9.5 REVERSE TRANSCRIPTION PCR
    • 9.5.1 HIGHER SENSITIVITY FOR MEASURING CHANGES IN GENE EXPRESSION TO AUGMENT MARKET GROWTH
  • 9.6 HOT-START PCR
    • 9.6.1 BETTER REACTION SPECIFICITY WITH LOWER ERROR RATES TO FAVOR MARKET GROWTH
  • 9.7 MULTIPLEX PCR
    • 9.7.1 COST-EFFECTIVENESS AND HIGH THROUGHPUT TO AID MARKET GROWTH
  • 9.8 OTHER PCR TECHNIQUES

10 PCR TECHNOLOGIES MARKET, BY APPLICATION

  • 10.1 INTRODUCTION
  • 10.2 DIAGNOSTIC APPLICATIONS
    • 10.2.1 UNAVAILABILITY OF REIMBURSEMENTS FOR CLINICAL DIAGNOSTIC TESTS TO LIMIT MARKET GROWTH
  • 10.3 GENOTYPING
    • 10.3.1 LARGE TARGET PATIENT POPULATION FOR CANCER DIAGNOSIS TO AUGMENT MARKET GROWTH
  • 10.4 NUCLEIC ACID DETECTION
    • 10.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO BOOST MARKET GROWTH
  • 10.5 GENE EXPRESSION ANALYSIS
    • 10.5.1 INCREASED R&D FUNDING AND GRANTS FOR PCR TO FAVOR MARKET GROWTH
  • 10.6 NUCLEIC ACID SYNTHESIS
    • 10.6.1 INCREASED FOCUS ON PERSONALIZED AND PRECISE MEDICINES TO SUPPORT MARKET GROWTH
  • 10.7 GENETIC SEQUENCING
    • 10.7.1 TECHNOLOGICAL IMPROVEMENTS AND REDUCED COSTS OF SEQUENCING TO FUEL MARKET GROWTH
  • 10.8 ENVIRONMENTAL APPLICATIONS
    • 10.8.1 STRICT GOVERNMENT ENVIRONMENTAL POLICIES TO PROMOTE USE OF PCR
  • 10.9 STANDARD VALIDATION/VERIFICATION
    • 10.9.1 NEED FOR REGIONAL/GLOBAL VALIDATION FOR COMMERCIAL/NON-COMMERCIAL GUIDELINE FRAMING TO DRIVE MARKET
  • 10.10 OTHER APPLICATIONS

11 PCR TECHNOLOGIES MARKET, BY END USER

  • 11.1 INTRODUCTION
  • 11.2 HOSPITAL LABORATORIES
    • 11.2.1 RISING PUBLIC AWARENESS OF ROUTINE CHECKUPS TO SUPPORT MARKET GROWTH
  • 11.3 DIAGNOSTIC LABORATORIES
    • 11.3.1 ESTABLISHMENT OF INDEPENDENT SPECIALIZED DIAGNOSTIC LABORATORIES TO PROPEL MARKET GROWTH
  • 11.4 ACADEMIC AND GOVERNMENT ORGANIZATIONS
    • 11.4.1 INCREASED GOVERNMENT SUPPORT FOR GENOME-BASED RESEARCH TO DRIVE MARKET
  • 11.5 PHARMA-BIOTECH COMPANIES
    • 11.5.1 INCREASING R&D INITIATIVES BY PHARMA-BIOTECH COMPANIES TO DRIVE ADOPTION OF PCR TECHNOLOGIES
  • 11.6 OTHER END USERS

12 PCR TECHNOLOGIES MARKET, BY REGION

  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    • 12.2.1 US
      • 12.2.1.1 US to dominate North American PCR technologies market during study period
    • 12.2.2 CANADA
      • 12.2.2.1 Supportive government initiatives for genomics research to aid market growth
  • 12.3 EUROPE
    • 12.3.1 GERMANY
      • 12.3.1.1 Presence of well-established pharmaceutical and R&D industry to augment market growth
    • 12.3.2 FRANCE
      • 12.3.2.1 Increasing investments in life science R&D for infrastructural development to favor market growth
    • 12.3.3 UK
      • 12.3.3.1 Rising acceptance of genome-based diagnosis by clinicians and healthcare professionals to spur market growth
    • 12.3.4 ITALY
      • 12.3.4.1 Supportive government policies and high healthcare expenditure to boost market growth
    • 12.3.5 SPAIN
      • 12.3.5.1 Increasing funding for life science research and pharmaceutical drug development to boost market growth
    • 12.3.6 REST OF EUROPE
  • 12.4 ASIA PACIFIC
    • 12.4.1 CHINA
      • 12.4.1.1 Improved public access to modern healthcare facilities and advanced genomics research to fuel market growth
    • 12.4.2 JAPAN
      • 12.4.2.1 Well-established healthcare infrastructure and advanced cancer research activities to support market growth
    • 12.4.3 INDIA
      • 12.4.3.1 Presence of large target patient population and high government healthcare expenditure to support market growth
    • 12.4.4 AUSTRALIA
      • 12.4.4.1 High healthcare expenditure to drive adoption of advanced PCR technologies
    • 12.4.5 SOUTH KOREA
      • 12.4.5.1 Improved medical tourism and prevalence of chronic diseases to propel market growth
    • 12.4.6 REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    • 12.5.1 BRAZIL
      • 12.5.1.1 Growing focus on proteomics and genomics research to drive market
    • 12.5.2 MEXICO
      • 12.5.2.1 Favorable trade agreements to support imports and improve accessibility to PCR instruments
    • 12.5.3 REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 GCC COUNTRIES
      • 12.6.1.1 Advancements in healthcare infrastructure and increased focus on personalized medicines to fuel market growth
    • 12.6.2 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET
  • 13.3 REVENUE ANALYSIS, 2022-2025
  • 13.4 MARKET SHARE ANALYSIS, 2025
    • 13.4.1 PCR INSTRUMENTS MARKET SHARE, BY KEY PLAYER, 2025
    • 13.4.2 PCR REAGENTS AND CONSUMABLES MARKET SHARE, BY KEY PLAYER, 2025
    • 13.4.3 GLOBAL PCR SOFTWARE AND SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 13.5.1 STARS
    • 13.5.2 EMERGING LEADERS
    • 13.5.3 PERVASIVE PLAYERS
    • 13.5.4 PARTICIPANTS
    • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 13.5.5.1 Company footprint
      • 13.5.5.2 Product footprint
      • 13.5.5.3 Application footprint
      • 13.5.5.4 Technique footprint
      • 13.5.5.5 End user footprint
      • 13.5.5.6 Region footprint
  • 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 13.6.1 PROGRESSIVE COMPANIES
    • 13.6.2 RESPONSIVE COMPANIES
    • 13.6.3 DYNAMIC COMPANIES
    • 13.6.4 STARTING BLOCKS
    • 13.6.5 COMPANY BENCHMARKING: STARTUPS/SMES, 2025
      • 13.6.5.1 Detailed list of key startups/SMEs players
      • 13.6.5.2 Competitive benchmarking of key startups/SMEs
  • 13.7 COMPANY VALUATION AND FINANCIAL METRICS, 2025
  • 13.8 PRODUCT/BRAND COMPARISON
  • 13.9 COMPETITIVE SCENARIO
    • 13.9.1 PRODUCT LAUNCHES AND APPROVALS
    • 13.9.2 DEALS
    • 13.9.3 EXPANSIONS

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS
    • 14.1.1 THERMO FISHER SCIENTIFIC INC.
      • 14.1.1.1 Business overview
      • 14.1.1.2 Products/Services/Solutions offered
      • 14.1.1.3 Recent developments
        • 14.1.1.3.1 Product launches and approvals
        • 14.1.1.3.2 Deals
      • 14.1.1.4 MnM view
        • 14.1.1.4.1 Key strengths
        • 14.1.1.4.2 Strategic choices
        • 14.1.1.4.3 Weaknesses and competitive threats
    • 14.1.2 F. HOFFMANN-LA ROCHE LTD.
      • 14.1.2.1 Business overview
      • 14.1.2.2 Products/Services/Solutions offered
      • 14.1.2.3 Recent developments
        • 14.1.2.3.1 Product launches and approvals
        • 14.1.2.3.2 Deals
      • 14.1.2.4 MnM view
        • 14.1.2.4.1 Key strengths
        • 14.1.2.4.2 Strategic choices
        • 14.1.2.4.3 Weaknesses and competitive threats
    • 14.1.3 AGILENT TECHNOLOGIES, INC.
      • 14.1.3.1 Business overview
      • 14.1.3.2 Products/Services/Solutions offered
      • 14.1.3.3 Recent developments
        • 14.1.3.3.1 Deals
        • 14.1.3.3.2 Other developments
      • 14.1.3.4 MnM view
        • 14.1.3.4.1 Key strengths
        • 14.1.3.4.2 Strategic choices
        • 14.1.3.4.3 Weaknesses and competitive threats
    • 14.1.4 BIO-RAD LABORATORIES, INC.
      • 14.1.4.1 Business overview
      • 14.1.4.2 Products/Services/Solutions offered
      • 14.1.4.3 Recent developments
        • 14.1.4.3.1 Product launches
        • 14.1.4.3.2 Deals
      • 14.1.4.4 MnM view
        • 14.1.4.4.1 Key strengths
        • 14.1.4.4.2 Strategic choices
        • 14.1.4.4.3 Weaknesses and competitive threats
    • 14.1.5 QIAGEN
      • 14.1.5.1 Business overview
      • 14.1.5.2 Products/Services/Solutions offered
      • 14.1.5.3 Recent developments
        • 14.1.5.3.1 Product launches and approvals
        • 14.1.5.3.2 Deals
        • 14.1.5.3.3 Expansions
      • 14.1.5.4 MnM view
        • 14.1.5.4.1 Key strengths
        • 14.1.5.4.2 Strategic choices
        • 14.1.5.4.3 Weaknesses and competitive threats
    • 14.1.6 DANAHER CORPORATION
      • 14.1.6.1 Business overview
      • 14.1.6.2 Products/Services/Solutions offered
      • 14.1.6.3 Recent developments
        • 14.1.6.3.1 Product approvals
        • 14.1.6.3.2 Deals
        • 14.1.6.3.3 Expansions
    • 14.1.7 BBOTT
      • 14.1.7.1 Business overview
      • 14.1.7.2 Products/Services/Solutions offered
      • 14.1.7.3 Recent developments
        • 14.1.7.3.1 Deals
    • 14.1.8 TAKARA BIO INC.
      • 14.1.8.1 Business overview
      • 14.1.8.2 Products/Services/Solutions offered
      • 14.1.8.3 Recent developments
        • 14.1.8.3.1 Product launches
        • 14.1.8.3.2 Deals
    • 14.1.9 ANALYTIK JENA GMBH+CO. KG
      • 14.1.9.1 Business overview
      • 14.1.9.2 Products/Services/Solutions offered
      • 14.1.9.3 Recent developments
        • 14.1.9.3.1 Product launches
        • 14.1.9.3.2 Deals
    • 14.1.10 EPPENDORF SE
      • 14.1.10.1 Business overview
      • 14.1.10.2 Products/Services/Solutions offered
      • 14.1.10.3 Recent developments
        • 14.1.10.3.1 Product launches and approvals
        • 14.1.10.3.2 Deals
    • 14.1.11 MERCK KGAA
      • 14.1.11.1 Business overview
      • 14.1.11.2 Products/Services/Solutions offered
        • 14.1.11.2.1 Deals
        • 14.1.11.2.2 Expansions
    • 14.1.12 BIONEER CORPORATION
      • 14.1.12.1 Business overview
      • 14.1.12.2 Products/Services/Solutions offered
      • 14.1.12.3 Recent developments
        • 14.1.12.3.1 Other developments
    • 14.1.13 REVVITY
      • 14.1.13.1 Business overview
      • 14.1.13.2 Products/Services/Solutions offered
      • 14.1.13.3 Recent developments
        • 14.1.13.3.1 Product launches
        • 14.1.13.3.2 Other developments
    • 14.1.14 BECTON, DICKINSON AND COMPANY
      • 14.1.14.1 Business overview
      • 14.1.14.2 Products/Services/Solutions offered
      • 14.1.14.3 Recent developments
        • 14.1.14.3.1 Product launches and approvals
        • 14.1.14.3.2 Deals
    • 14.1.15 BIOMERIEUX
      • 14.1.15.1 Business overview
      • 14.1.15.2 Products/Services/Solutions offered
      • 14.1.15.3 Recent developments
        • 14.1.15.3.1 Product launches and approvals
    • 14.1.16 STANDARD BIOTOOLS
      • 14.1.16.1 Business overview
      • 14.1.16.2 Products/Services/Solutions offered
    • 14.1.17 HOLOGIC, INC.
      • 14.1.17.1 Business overview
      • 14.1.17.2 Products/Services/Solutions offered
      • 14.1.17.3 Recent developments
        • 14.1.17.3.1 Product launches
    • 14.1.18 LONZA
      • 14.1.18.1 Business overview
      • 14.1.18.2 Products/Services/Solutions offered
    • 14.1.19 ILLUMINA, INC.
      • 14.1.19.1 Business overview
      • 14.1.19.2 Products/Services/Solutions offered
    • 14.1.20 SANSURE BIOTECH INC.
      • 14.1.20.1 Business overview
      • 14.1.20.2 Products/Services/Solutions offered
  • 14.2 OTHER PLAYERS
    • 14.2.1 PROMEGA CORPORATION
    • 14.2.2 LIMING BIO
    • 14.2.3 TRANSGEN BIOTECH CO., LTD.
    • 14.2.4 DAAN GENE CO., LTD.
    • 14.2.5 BIOBASE GROUP
    • 14.2.6 NIPPON GENETICS EUROPE
    • 14.2.7 STILLA
    • 14.2.8 GENSCRIPT
    • 14.2.9 NEW ENGLAND BIOLABS

15 RESEARCH METHODOLOGY

  • 15.1 RESEARCH DATA
  • 15.2 RESEARCH DESIGN
    • 15.2.1 SECONDARY RESEARCH
      • 15.2.1.1 Key secondary sources
      • 15.2.1.2 Key objectives of secondary research
      • 15.2.1.3 Key data from secondary sources
    • 15.2.2 PRIMARY RESEARCH
      • 15.2.2.1 Key primary sources
      • 15.2.2.2 Key objectives of primary research
      • 15.2.2.3 Key industry insights
      • 15.2.2.4 Breakdown of primaries
  • 15.3 MARKET SIZE ESTIMATION
    • 15.3.1 BOTTOM-UP APPROACH
      • 15.3.1.1 Company revenue estimation approach
      • 15.3.1.2 Customer-based market estimation
      • 15.3.1.3 Top-down approach
      • 15.3.1.4 Primary interviews
    • 15.3.2 GROWTH FORECAST
  • 15.4 DATA TRIANGULATION
  • 15.5 MARKET SHARE ASSESSMENT
  • 15.6 STUDY ASSUMPTIONS
  • 15.7 GROWTH ASSUMPTIONS
  • 15.8 RISK ASSESSMENT
  • 15.9 RESEARCH LIMITATIONS

16 APPENDIX

  • 16.1 DISCUSSION GUIDE
  • 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 16.3 CUSTOMIZATION OPTIONS
  • 16.4 RELATED REPORTS
  • 16.5 AUTHOR DETAILS
Show more
Product Code: AST 7880

List of Tables

  • TABLE 1 PCR TECHNOLOGIES MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 ADVANTAGES AND DISADVANTAGES OF REAL-TIME POINT-OF-CARE RT-PCR DEVICES
  • TABLE 3 PCR TECHNOLOGIES MARKET: UNMET NEEDS
  • TABLE 4 STRATEGIC FOCUS OF TIER-1/2/3 PLAYERS
  • TABLE 5 PCR TECHNOLOGIES MARKET: PORTER'S FIVE FORCES
  • TABLE 6 PCR TECHNOLOGIES MARKET: ROLE IN ECOSYSTEM
  • TABLE 7 INDICATIVE PRICING OF PCR SYSTEMS, BY KEY PLAYER, 2025
  • TABLE 8 INDICATIVE PRICING OF PCR TECHNOLOGY-BASED PRODUCTS, BY REGION, 2023-2025 (USD)
  • TABLE 9 IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021-2025 (USD THOUSAND)
  • TABLE 10 EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021-2025 (USD THOUSAND)
  • TABLE 11 PCR TECHNOLOGIES MARKET: KEY CONFERENCES AND EVENTS, 2026-2027
  • TABLE 12 US ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 13 INNOVATIONS AND PATENT REGISTRATIONS, 2021-2026
  • TABLE 14 KEY COMPANIES IMPLEMENTING AI/GEN AI IN PCR TECHNOLOGIES MARKET
  • TABLE 15 KEY APPLICATIONS AND INDUSTRIAL OUTCOMES ENABLED BY PCR TECHNOLOGIES
  • TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
  • TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
  • TABLE 18 PCR TECHNOLOGIES MARKET: UNMET NEED ANALYSIS
  • TABLE 19 US: CLASSIFICATION OF PCR TECHNOLOGY-ASSOCIATED DIAGNOSTIC DEVICES
  • TABLE 20 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 21 EUROPE: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 22 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 23 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 28 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 29 PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 30 PCR TECHNOLOGIES MARKET FOR REAGENTS AND CONSUMABLES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 31 PCR TECHNOLOGIES MARKET FOR INSTRUMENTS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 32 PCR TECHNOLOGIES MARKET FOR SOFTWARE AND SERVICES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 33 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 34 REAL-TIME PCR MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 35 CONVENTIONAL PCR MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 36 DIGITAL PCR MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 37 ONE-STEP RT-PCR VS. TWO-STEP RT-PCR
  • TABLE 38 REVERSE TRANSCRIPTION PCR MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 39 BENEFITS AND CONSIDERATIONS OF HOT-START PCR TECHNOLOGY
  • TABLE 40 HOT-START PCR MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 41 MULTIPLEX PCR MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 42 OTHER PCR TECHNIQUES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 43 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 44 PCR TECHNOLOGIES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 45 PCR TECHNOLOGIES MARKET FOR GENOTYPING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 46 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID DETECTION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 47 PCR TECHNOLOGIES MARKET FOR GENE EXPRESSION ANALYSIS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 48 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID SYNTHESIS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 49 PCR TECHNOLOGIES MARKET FOR GENETIC SEQUENCING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 50 PCR TECHNOLOGIES MARKET FOR ENVIRONMENTAL APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 51 PCR TECHNOLOGIES MARKET FOR STANDARD VALIDATION/VERIFICATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 52 PCR TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 53 PCR TECHNOLOGIES MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 54 PCR TECHNOLOGIES MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 55 PCR TECHNOLOGIES MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 56 PCR TECHNOLOGIES MARKET FOR ACADEMIC AND GOVERNMENT ORGANIZATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 57 PCR TECHNOLOGIES MARKET FOR PHARMA-BIOTECH COMPANIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 58 PCR TECHNOLOGIES MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 59 PCR TECHNOLOGIES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 60 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 61 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 62 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 63 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 64 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 65 US: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 66 US: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 67 CANADA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 68 CANADA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 69 EUROPE: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 70 EUROPE: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 71 EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 72 EUROPE: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 73 EUROPE: PCR TECHNOLOGIES MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 74 GERMANY: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 75 GERMANY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 76 FRANCE: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 77 FRANCE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 78 UK: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 79 UK: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 80 ITALY: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 81 ITALY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 82 SPAIN: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 83 SPAIN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 84 REST OF EUROPE : PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 85 REST OF EUROPE : PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 86 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 87 ASIA PACIFIC : PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 88 ASIA PACIFIC : PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 89 ASIA PACIFIC : PCR TECHNOLOGIES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 90 ASIA PACIFIC : PCR TECHNOLOGIES MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 91 CHINA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 92 CHINA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 93 JAPAN: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 94 JAPAN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 95 INDIA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 96 INDIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 97 AUSTRALIA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 98 AUSTRALIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 99 SOUTH KOREA : PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 100 SOUTH KOREA : PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 101 REST OF ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 102 REST OF ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 103 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 104 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 105 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 106 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 107 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 108 BRAZIL: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 109 BRAZIL: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 110 MEXICO : PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 111 MEXICO: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 112 REST OF LATIN AMERICA : PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 113 REST OF LATIN AMERICA : PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 114 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 115 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 116 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 117 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 118 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 119 GCC COUNTRIES: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 120 GCC COUNTRIES: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 121 REST OF THE MIDDLE EAST & AFRICA : PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 122 REST OF THE MIDDLE EAST & AFRICA : PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 123 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET
  • TABLE 124 PCR TECHNOLOGIES MARKET: DEGREE OF COMPETITION
  • TABLE 125 PCR TECHNOLOGIES MARKET: PRODUCT FOOTPRINT
  • TABLE 126 PCR TECHNOLOGIES MARKET: APPLICATION FOOTPRINT
  • TABLE 127 PCR TECHNOLOGIES MARKET: TECHNIQUE FOOTPRINT
  • TABLE 128 PCR TECHNOLOGIES MARKET: END USER FOOTPRINT
  • TABLE 129 PCR TECHNOLOGIES MARKET: REGION FOOTPRINT
  • TABLE 130 PCR TECHNOLOGIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES PLAYERS
  • TABLE 131 PCR TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 132 PCR TECHNOLOGIES MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 133 PCR TECHNOLOGIES MARKET: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 134 PCR TECHNOLOGIES MARKET: EXPANSIONS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 135 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 136 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 137 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 138 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 139 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 140 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 141 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 142 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 143 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 144 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 145 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 146 AGILENT TECHNOLOGIES, INC.: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 147 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 148 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 149 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022-SEPTEMBER 2026
  • TABLE 150 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 151 QIAGEN: COMPANY OVERVIEW
  • TABLE 152 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 153 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 154 QIAGEN: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 155 QIAGEN: EXPANSIONS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 156 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 157 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 158 DANAHER CORPORATION: PRODUCT APPROVALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 159 DANAHER CORPORATION: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 160 DANAHER CORPORATION: EXPANSIONS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 161 ABBOTT: COMPANY OVERVIEW
  • TABLE 162 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 163 ABBOTT: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 164 TAKARA BIO INC.: COMPANY OVERVIEW
  • TABLE 165 TAKARA BIO INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 166 TAKARA BIO INC.: PRODUCT LAUNCHES, JANUARY 2022-SEPTEMBER 2026
  • TABLE 167 TAKARA BIO INC.: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 168 ANALYTIK JENA GMBH+CO. KG: COMPANY OVERVIEW
  • TABLE 169 ANALYTIK JENA GMBH+CO. KG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 170 ANALYTIK JENA GMBH+CO. KG: PRODUCT LAUNCHES, JANUARY 2022-SEPTEMBER 2026
  • TABLE 171 ANALYTIK JENA GMBH+CO. KG: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 172 EPPENDORF SE: COMPANY OVERVIEW
  • TABLE 173 EPPENDORF SE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 174 EPPENDORF SE: PRODUCT LAUNCHES, JANUARY 2022-SEPTEMBER 2026
  • TABLE 175 EPPENDORF SE: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 176 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 177 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 178 MERCK KGAA: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 179 MERCK KGAA: EXPANSIONS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 180 BIONEER CORPORATION: COMPANY OVERVIEW
  • TABLE 181 BIONEER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 182 BIONEER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 183 REVVITY: COMPANY OVERVIEW
  • TABLE 184 REVVITY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 185 REVVITY: PRODUCT LAUNCHES, JANUARY 2022-SEPTEMBER 2026
  • TABLE 186 REVVITY: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 187 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 188 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 189 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 190 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 191 BIOMERIEUX: COMPANY OVERVIEW
  • TABLE 192 BIOMERIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 193 BIOMERIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 194 STANDARD BIOTOOLS: COMPANY OVERVIEW
  • TABLE 195 STANDARD BIOTOOLS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 196 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 197 HOLOGIC, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 198 HOLOGIC, INC.: PRODUCT LAUNCHES, JANUARY 2022-SEPTEMBER 2026
  • TABLE 199 LONZA: COMPANY OVERVIEW
  • TABLE 200 LONZA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 201 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 202 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 203 SANSURE BIOTECH INC.: COMPANY OVERVIEW
  • TABLE 204 SANSURE BIOTECH INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 205 PROMEGA CORPORATION: COMPANY OVERVIEW
  • TABLE 206 LIMINGBIO: COMPANY OVERVIEW
  • TABLE 207 TRANSGEN BIOTECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 208 DAAN GENE CO., LTD.: COMPANY OVERVIEW
  • TABLE 209 BIOBASE GROUP: COMPANY OVERVIEW
  • TABLE 210 NIPPON GENETICS EUROPE: COMPANY OVERVIEW
  • TABLE 211 STILLA: COMPANY OVERVIEW
  • TABLE 212 GENSCRIPT: COMPANY OVERVIEW
  • TABLE 213 NEW ENGLAND BIOLABS: COMPANY OVERVIEW
  • TABLE 214 PCR TECHNOLOGIES MARKET: STUDY ASSUMPTIONS
  • TABLE 215 PCR TECHNOLOGIES MARKET: RISK ASSESSMENT

List of Figures

  • FIGURE 1 PCR TECHNOLOGIES MARKET: SEGMENTS CONSIDERED
  • FIGURE 2 PCR TECHNOLOGIES MARKET: YEARS CONSIDERED
  • FIGURE 3 MARKET SCENARIO
  • FIGURE 4 GLOBAL PCR TECHNOLOGIES MARKET, 2024-2031
  • FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET, 2022-2026
  • FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF PCR TECHNOLOGIES MARKET
  • FIGURE 7 HIGH-GROWTH SEGMENTS IN PCR TECHNOLOGIES MARKET, 2025
  • FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PCR TECHNOLOGIES MARKET DURING FORECAST PERIOD
  • FIGURE 9 NORTH AMERICA TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD
  • FIGURE 10 REAGENTS AND CONSUMABLES ACCOUNTED FOR LARGEST MARKET SHARE IN ASIA PACIFIC IN 2025
  • FIGURE 11 CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2025 TO 2031
  • FIGURE 12 PCR TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 13 PCR TECHNOLOGIES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 14 PCR TECHNOLOGIES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 15 PCR TECHNOLOGIES MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 16 AVERAGE SELLING PRICE OF CONVENTIONAL PCR INSTRUMENTS, BY KEY PLAYER, 2025
  • FIGURE 17 AVERAGE SELLING PRICE OF PCR TECHNOLOGY-BASED PRODUCTS, BY REGION, 2023-2025
  • FIGURE 18 IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021-2025 (USD THOUSAND)
  • FIGURE 19 EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021-2025 (USD THOUSAND)
  • FIGURE 20 TRENDS/DISRUPTIONS INFLUENCING CUSTOMER BUSINESS
  • FIGURE 21 INVESTMENT AND FUNDING SCENARIO, 2019-2023
  • FIGURE 22 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019-2023
  • FIGURE 23 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2019-2023 (USD MILLION)
  • FIGURE 24 PATENTS APPLIED AND GRANTED, 2016-2026
  • FIGURE 25 PCR TECHNOLOGIES MARKET: IMPACT OF AI/GEN AI
  • FIGURE 26 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
  • FIGURE 27 KEY BUYING CRITERIA FOR TOP FOUR END USERS
  • FIGURE 28 NORTH AMERICA: PCR TECHNOLOGIES MARKET SNAPSHOT
  • FIGURE 29 ASIA PACIFIC: PCR TECHNOLOGIES MARKET SNAPSHOT
  • FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN PCR TECHNOLOGIES MARKET, 2022-2025
  • FIGURE 31 PCR INSTRUMENTS MARKET SHARE ANALYSIS, 2025
  • FIGURE 32 PCR REAGENTS AND CONSUMABLES MARKET SHARE ANALYSIS, 2025
  • FIGURE 33 PCR SOFTWARE AND SERVICES MARKET SHARE ANALYSIS (2025)
  • FIGURE 34 PCR TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 35 PCR TECHNOLOGIES MARKET: COMPANY FOOTPRINT
  • FIGURE 36 PCR TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 37 EV/EBITDA OF KEY VENDORS, 2025
  • FIGURE 38 YTD TOTAL RETURN AND 5-YEAR STOCK BETA VALUE FOR KEY PCR TECHNOLOGY VENDORS
  • FIGURE 39 PCR TECHNOLOGIES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 40 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • FIGURE 42 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • FIGURE 43 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
  • FIGURE 44 QIAGEN: COMPANY SNAPSHOT
  • FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 46 ABBOTT: COMPANY SNAPSHOT
  • FIGURE 47 TAKARA BIO INC.: COMPANY SNAPSHOT
  • FIGURE 48 EPPENDORF SE: COMPANY SNAPSHOT
  • FIGURE 49 MERCK KGAA: COMPANY SNAPSHOT
  • FIGURE 50 BIONEER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 51 REVVITY: COMPANY SNAPSHOT
  • FIGURE 52 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 53 BIOMERIEUX: COMPANY SNAPSHOT
  • FIGURE 54 STANDARD BIOTOOLS: COMPANY SNAPSHOT
  • FIGURE 55 HOLOGIC, INC.: COMPANY SNAPSHOT
  • FIGURE 56 LONZA: COMPANY SNAPSHOT
  • FIGURE 57 ILLUMINA, INC.: COMPANY SNAPSHOT
  • FIGURE 58 SANSURE BIOTECH INC.: COMPANY SNAPSHOT
  • FIGURE 59 PCR TECHNOLOGIES MARKET: RESEARCH DATA
  • FIGURE 60 PCR TECHNOLOGIES MARKET: RESEARCH DESIGN
  • FIGURE 61 PCR TECHNOLOGIES MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 62 PCR TECHNOLOGIES MARKET: KEY PRIMARY SOURCES (DEMAND AND SUPPLY SIDES)
  • FIGURE 63 PCR TECHNOLOGIES MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS
  • FIGURE 64 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 65 BREAKDOWN OF PRIMARIES: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 66 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 67 PCR TECHNOLOGIES MARKET SIZE ESTIMATION: COMPANY REVENUE ESTIMATION
  • FIGURE 68 PCR TECHNOLOGIES MARKET: BOTTOM-UP APPROACH
  • FIGURE 69 PCR TECHNOLOGIES MARKET: TOP-DOWN APPROACH
  • FIGURE 70 DATA TRIANGULATION METHODOLOGY
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!